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Abstract
Background: Liver cirrhosis is associated with high morbidity and mortality. MicroRNAs (miRs) circulating in the blood are an
emerging new class of biomarkers. In particular, the serum level of the liver-specific miR-122 might be a clinically useful new
parameter in patients with acute or chronic liver disease.
Aim: Here we investigated if the serum level of miR-122 might be a prognostic parameter in patients with liver cirrhosis.
Methods: 107 patients with liver cirrhosis in the test cohort and 143 patients in the validation cohort were prospectively
enrolled into the present study. RNA was extracted from the sera obtained at the time of study enrollment and the level of
miR-122 was assessed. Serum miR-122 levels were assessed by quantitative reverse-transcription PCR (RT-PCR) and were
compared to overall survival time and to different complications of liver cirrhosis.
Results: Serum miR-122 levels were reduced in patients with hepatic decompensation in comparison to patients with
compensated liver disease. Patients with ascites, spontaneous bacterial peritonitis and hepatorenal syndrome had
significantly lower miR-122 levels than patients without these complications. Multivariate Cox regression analysis revealed
that the miR-122 serum levels were associated with survival independently from the MELD score, sex and age.
Conclusions: Serum miR-122 is a new independent marker for prediction of survival of patients with liver cirrhosis.
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Introduction
End stage liver disease is associated with high morbidity and
mortality. When hepatic decompensation has occurred, the
morbidity increases rapidly. After the first manifestation of ascites
the one year mortality increases up to 40% [1,2]. The patients’
prognosis further deteriorates upon occurrence of spontaneous
bacterial peritonitis or hepatorenal syndrome. Also variceal
bleeding has a high impact on the death rate (around 20%) in
every episode in patients with liver cirrhosis [3]. The assessment of
the risk of death in these patients is of high interest and importance
to optimize the time point for organ allocation if liver trans-
plantation is indicated [4]. Initially developed for estimating risks
in patients undergoing transjugular portosystemic shunt procedure
[5], the model of end stage liver disease (MELD) score has now
been used for several years to attribute the risk of death for patients
with liver cirrhosis, rendering it the lead parameter for allocation
of livers for transplantation [6,7]. The MELD score is also
predictive for patients with complications of liver cirrhosis such as
acute bleeding or hepatorenal syndrome [8,9]. However, the
MELD score has some shortcomings as it does not include all
complications of liver cirrhosis, e.g. ascites or hepatic encepha-
lopathy. Furthermore, the MELD score was developed for
prediction of short term survival within 3 months. Predictivity
for survival of more than 3 months is much weaker [6]. Therefore,
the evaluation of new markers is an important task in patients with
liver cirrhosis.
MicroRNAs (miRs), evolutionary highly conserved, small (18–
25 ribonucleotides) non-coding RNAs, are involved in the
regulation of virtually all cell functions [10]. They currently
emerge as a new class of biomarkers [11–13]. Dysregulated miRs
play pivotal roles in the pathogenesis of various diseases and
characteristic miR pattern have been found in pathological tissues
[14]. In the liver miR-122 accounts for approximately 70% of all
miRs and is important for the functional state of the hepatocyte,
whereas other organs express much lower amounts of this miR
[15,16]. miR-122 regulates many genes in the liver that control the
cell cycle, differentiation, proliferation and apoptosis [17]. Loss of
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a malignant phenotype [18]. miRs, probably in large part derived
from cells with damaged plasma membrane [19], also circulate in
the blood in a cell-free and relatively stable form [13]. Differences
in the concentration of certain miRs have been found between
sera or plasma from patients with cancer, inflammatory or
cardiovascular diseases, rendering cell-free blood-derived miRs
a highly promising new class of disease markers [12]. However, to
fully evaluate the diagnostic potential of serum- or plasma-derived
miRs, further clinical studies, in particular prospective studies, are
necessary.
Elevated levels of the liver-specific miR-122 have been found in
sera or plasma from humans and rodents upon toxic liver injury
[20–22] as well as in sera or plasma of patients with chronic
hepatitis B or C infection [23–26], rendering miR-122 a promising
specific marker for liver diseases. The suitability of cell-free miRs
in the blood to predict patient survival of patients with liver
diseases is presently unknown. To investigate if miR-122 might be
a prognostic parameter in patients with liver cirrhosis, we
examined miR-122 levels in sera from patients with compensated
and decompensated liver cirrhosis and correlated the serum miR-
122 levels with patient survival, development of complications and
standard laboratory parameters in a prospective clinical study.
Methods
Ethics statement
All patients gave their written informed consent. The study was
approved by the Ethics Committee of the Goethe University
Frankfurt, Germany. The study was performed in accordance with
the 1975 Declaration of Helsinki and the REMARK (Reporting
recommendations for tumor marker prognostic studies) guidelines.
Selection of patients
Patients with liver cirrhosis who were admitted to our liver unit
from May 2009 until May 2010 were prospectively enrolled into
the present study. Inclusion criteria were liver cirrhosis assessed by
histopathological examination or pathognomonic results in
abdominal ultrasound examination, computer tomography or
magnetic resonance imaging. Only in patients with inexplicit
stages of fibrosis or unclear cause of liver disease biopsy was
performed. In patients with characteristic sonomorphologic
criteria of cirrhosis or decompensated liver disease no liver biopsy
was performed. Exclusion criteria were an age below 18 years,
former liver transplantation and a history of cancer within the last
five years other than hepatocellular carcinoma. At the day of
informed consent and enrollment of patients, blood samples were
obtained for the analyses and were also tested for routine
parameters of clinical chemistry. Furthermore, symptoms of
hepatic decompensation (variceal bleeding, ascites, spontaneous
bacterial peritonitis, hepatorenal syndrome or hepatic encepha-
lopathy) were assessed. The primary end point was overall survival
Table 1. Patient characteristics.
Parameter Test cohort
Validation
cohort
Epidemiology
Patients 107 143
Gender, male/female, n (%) 71/36 (66.4/33.6) 96/47 (67.1/32.9)
Age, years, median, SD 57611.3 58611.7
Etiology of liver cirrhosis
Alcohol abuse, n (%) 60 (56.1) 65 (45.5)
Hepatitis C, n (%) 32 (29.9) 34 (23.8)
Hepatitis B, n (%) 13 (12.1) 18 (12.6)
Hepatitis D, n (%) 1 (0.9) 0 (0.0)
Primary sclerosing
cholangitis, n (%)
4 (3.7) 11 (7.7)
Autoimmune hepatitis, n (%) 4 (3.7) 5 (3.5)
Non alcoholic
steatohepatitis, n (%)
4 (3.7) 2 (1.4)
Alpha1-antitrypsin
deficiency, n (%)
1 (0.9) 0 (0.0)
Cardiac cirrhosis, n (%) 1 (0.9) 0 (0.0)
Cryptogenic, n (%) 6 (5.6) 18 (12.6)
Budd-Chiari syndrome, n (%) 1 (0.9) 0 (0.0)
Hemochromatosis, n (%) 3 (2.8) 4 (2.8)
Primary biliary cirrhosis 0 (0.0) 3 (2.1)
Hepatocellular carcinoma,
n( % )
15 (14.0) 23 (16.1)
MELD
1, mean, SD 16671 4 66
Laboratory results
Sodium
2 (mmol/l), median, SD 13865.1 13965.3
ALT
3 (U/l), median, SD 306157 336126
AST
4 (U/l), median, SD 556125 506239
GGT
5 (U/l), median, SD 996196 1086202
ALP
6 (U/l), median, SD 114682 126694
Albumin
7 (g/dl), median, SD 3.260.6 3.260.7
Bilirubin
8 (mg/dl), median, SD 2.365.8 1.864.6
INR
9, median, SD 1.4860.48 1.3160.36
Creatinine
10 (mg/dl), median, SD 1.0860.88 0.9160.68
Abbreviations:
1model of end stage liver disease,
2normal value: 135–
145 mmol/l
3alanine aminotransferase (normal values: female: 10–35 U/l, male:
10–50 U/l),
4aspartate aminotransferase (normal values: female: ,35 U/l, male:
,40 U/l),
5c-glutamyltransferase (normal values: female: ,40 U/l, male: ,60 U/
l),
6alkaline phosphatase (normal values: female: 55–105 U/l, male: 40–130 U/l),
7normal values: 3.5–5.2 mg/dl,
8normal values: ,1 mg/dl,
9international
normalized ratio,
10normal values: female: 0.5–0.9 mg/dl, male: 0.7–1.2 mg/dl.
doi:10.1371/journal.pone.0045652.t001
Figure 1. Serum miR-122 levels in cirrhotic patients with and
without hepatic decompensation. The vertical lines indicate the
range, the horizontal boundaries of the boxes represent the first and
third quartile. The number of patients in each group is indicated in the
figure.
doi:10.1371/journal.pone.0045652.g001
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until death, liver transplantation or last contact. Patients who
underwent liver transplantation were excluded from the study
from the day of transplantation. A flow chart showing the design of
the study is shown in Figure S1.
Validation cohort
The validation cohort consisted of a second cohort of cirrhotic
patients who were admitted to our hospital from October 2010
until May 2011 and were prospectively enrolled. Inclusion and
exclusion criteria were the same as in the test cohort. Follow-up
and assessment of overall survival were performed as in the test
cohort. All patients gave their written informed consent to
participate in the study.
Blood sampling
Peripheral blood was collected from each individual at the day
of enrollment into the study. The serum tubes were centrifuged at
15006g for 10 min at 4uC, followed by an additional centrifu-
gation step at 20006g4 uC to completely remove any remaining
cells. The serum samples were aliquoted and stored at 280uC
until further use.
Clinical chemistry
Standard parameters of liver and kidney function were
measured at the central laboratory of the Frankfurt University
Hospital.
Figure 2. Serum miR-122 levels in complications of liver cirrhosis. The vertical lines indicate the range, the horizontal boundaries of the
boxes represent the first and third quartile. The number of patients in each group is indicated in the figure.
doi:10.1371/journal.pone.0045652.g002
Serum miR-122 in Liver Cirrhosis
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e45652Detection of miRs by quantitative real-time reverse-
transcription (RT)-PCR
Isolation of serum RNA and quantification of the miR-122
levels were performed as described previously [24,25]. Total RNA
was extracted from 500 ml of serum with the miRVana RNA
isolation kit and TriReagentLS (Sigma-Aldrich, St. Louis, MO)
and chloroform according to the mirVana
TM miRNA isolation kit
protocol. cDNA was reverse transcribed from 5 ml of RNA with
the TaqMan miRNA reverse transcription kit. miR-122 levels
were assessed by a TaqMan miRNA assay specific for miR-122
from Applied Biosystems (ABI, Foster City, CA) on a StepOne
TM-
Plus Real-Time PCR System (ABI, Foster City, CA). Quantitative
real-time PCRs were performed in duplicates and means were
calculated. The results of quantitative PCR values were given as
negatives of the CT (cycle threshold) values which correlate with
the amount of miRs in the serum.
Statistical analysis
Data were analyzed using the BiAS software for windows
(version 9.11, Epsilon-Verlag, Darmstadt, Germany) and SPSS
version 20 (IBM, Chicago, IL). Death was considered as event.
Follow-up time was time until death or last contact to patient. In
patients who underwent liver transplantation the follow-up was
stopped at the day of liver transplantation. From the date of
transplantation the patients were excluded from further analysis.
Overall survival rates were assessed for all patients using the Cox
regression model. Survival curves were calculated with the Cox
model. Independent predictors of survival were determined with
a multivariate Cox regression analysis using forward stepwise
(likelihood ratio) entry. The nonparametric Wilcoxon-Mann-
Whitney and Kruskal-Wallis tests were used to determine
differences between groups of patients. A Bonferroni correction
was used when multiple subgroup comparisons were performed. P
values ,0.05 were considered to be significant. In the box plots
the vertical lines indicate the range, the horizontal boundaries of
the boxes represent the first and third quartile. The correlation
coefficients r were calculated by using the Spearman correlation.
Results
From May 2009 until May 2010 107 patients with liver cirrhosis
who were admitted to our liver unit at the Goethe University
Hospital were prospectively enrolled into the present study. The
patient characteristics are shown in Table 1. 90 patients (84.1%)
showed signs of hepatic decompensation (variceal bleeding, ascites,
hepatic encephalopathy, hepatorenal syndrome or spontaneous
bacterial peritonitis), whereas 17 patients had compensated liver
cirrhosis. Some patients had more than one etiology of chronic
liver disease. The mean duration (6 SD) of follow-up was
2206267 days. 26 of the 107 patients died within the study time.
14 patients underwent liver transplantation at the Goethe
University Hospital Frankfurt. The median MELD score at study
entry in the cohort of patients was 16.
Low serum miR-122 levels are associated with
decompensation of liver cirrhosis
miR-122 levels in sera of patients with and without hepatic
decompensation were assessed. Serum levels of miR-122 in
patients with hepatic decompensation were significantly lower
compared to patients with compensated liver disease (P=0.012)
(Figure 1). To assess if reduced miR-122 serum levels were
associated with complications of liver cirrhosis, the miR-122 serum
levels were examined in patients with and without ascites,
spontaneous bacterial peritonitis, hepatorenal syndrome, variceal
bleeding, hepatic encephalopathy and hepatocellular carcinoma.
As shown in Figure 2A–C, patients with ascites (P=0.007),
spontaneous bacterial peritonitis (P=0.003) or hepatorenal
syndrome (P=0.037) had significantly lower serum levels of
miR-122 than patients without the respective complication. In
contrast, no significant differences were observed between patients
with and without variceal bleeding (P=0.933), hepatic encepha-
lopathy (P=0.550) or hepatocellular carcinoma (P=0.132)
(Figure 2D–F).
Serum miR-122 levels correlate with parameters of liver
damage and hepatic functional capacity
Serum/plasma levels of miR-122 correlate with hepatic
necroinflammation, liver damage and aminotransferase levels in
acute and chronic liver diseases [22–26]. Therefore, the relation
between serum miR-122 levels and standard laboratory param-
eters in the cohort of patients with liver cirrhosis were investigated.
The results are displayed in Table 2. Highly significant
correlations were found between serum miR-122 levels and
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), c-glutamyltransferase (GGT) and alkaline phosphatase
(ALP), i. e. parameters of liver cell damage. Moreover, there was
a negative correlation between serum miR-122 levels and the
international normalized ratio (INR), an indicator of liver
function. In contrast, there were no significant relations between
miR-122 serum levels and the serum bilirubin, serum albumin and
total serum protein levels. There was a negative correlation
between the serum levels of miR-122 and creatinine, i. e. patients
with higher serum creatinine had lower miR-122 serum levels.
Finally, a significant correlation between the MELD score and
miR-122 levels were observed.
The serum miR-122 level is a marker for mortality in
patients with liver cirrhosis
The finding that patients with hepatic decompensation, who
have a worse prognosis than patients with compensated liver
cirrhosis, had lower miR-122 serum levels than patients with
compensated liver disease, led to the assumption that miR-122
might be of prognostic relevance in cirrhotic patients. Therefore,
the patients were grouped according to their miR-122 serum
concentration in tertiles. The distribution of serum miR-122 levels
Table 2. Correlation between miR-122 serum levels and
laboratory parameters.
Parameter
Rank correlation
coefficient (r) P
Alanine aminotransferase (U/l) 0.402 ,0.001
Aspartate aminotransferase (U/l) 0.358 ,0.001
c-glutamyltransferase (U/l) 0.365 ,0.001
Alkaline phosphatase (U/l) 0.400 ,0.001
Total serum protein (mg/dl) 0.071 0.465
Albumin (mg/dl) 0.069 0.481
International normalized ratio 20.331 ,0.001
Bilirubin (mg/dl) 20.076 0.434
Creatinine (mg/dl) 20.238 0.013
MELD
1 score 20.290 0.003
Abbreviation:
1Model of end stage liver disease.
doi:10.1371/journal.pone.0045652.t002
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with the highest miR-122 levels was compared to the two thirds of
patients with lower miR-122 serum concentration and a univariate
Cox regression analysis was performed. There was a significant
association between miR-122 levels and overall survival, i. e.
patients with low miR-122 levels showed shorter survival times
(P=0.016, hazard ratio 3.259, 95% confidence interval 1.252–
8.484). Survival curves illustrate the different survival times
between patients with low and high serum miR-122 concentra-
tions (Figure 3B).
To investigate if the miR-122 serum levels might be associated
with overall survival independently from the MELD score, an age
and sex adjusted multivariate Cox regression analysis using
forward stepwise (likelihood ratio) was performed. As shown in
Table 3, a low MELD score (P,0.001), male sex (P=0.005) and
low miR-122 serum levels (P=0.013) were independently associ-
ated with survival.
Validation of results in a second cohort of patients
To confirm the finding that miR-122 serum levels are lower in
patients with hepatic decompensation and are associated with
Figure 3. Serum miR-122 levels are associated with survival in patients with liver cirrhosis. (A) Distribution of serum miR-122 levels
throughout the patients. The cut-off value for the patient cohorts is marked in blue. (B) Survival curves for patients with high or low serum miR-122
levels. The analysis was performed with the Cox regression model.
doi:10.1371/journal.pone.0045652.g003
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143 patients with liver cirrhosis were prospectively enrolled from
October 2010 until May 2011 at the Liver Department of the
Goethe University Hospital. Patients’ characteristics are shown in
Table 1. The median follow-up time was 2326172 days. 21
patients died within the observation time and 13 patients
underwent liver transplantation. 109 of the 143 patients (76.2%)
showed decompensated liver disease.
Similar to the test cohort, in the validation cohort lower levels of
miR-122 were found in patients with hepatic decompensation
(P=0.026) (Figure 4A) and in patients with ascites (P=0.015)
(Figure 4B). Patients with lower serum miR-122 levels had also
a shorter overall survival time (P=0.049, hazard ratio 2.683, 95%
confidence interval 1.294–5.564) (Figure 4C).
Finally, the data of the two independent cohorts were combined
and univariate and multivariate sex and age adjusted Cox
regression with inclusion of the MELD score were performed. In
the univariate as well as in the multivariate analysis miR-122 was
significantly associated with overall survival (P=0.002, hazard
ratio 3.161, 95% confidence interval 1.539–6.494 and P=0.005,
hazard ratio 2.872, 95% confidence interval 1.371–6.014, re-
spectively). The overall survival curves for all patients according to
higher and lower miR-122 serum concentrations are shown in
Figure 4D.
Discussion
MicroRNAs in serum or plasma are increasingly recognized as
new potentially useful disease parameters readily accessible in the
blood. Although several studies have investigated the role of miRs
in liver diseases, prospective studies examining the role of serum or
plasma miRNAs in human diseases are still rare. Due to its almost
exclusive expression in the liver, the presence of miR-122 in serum
is highly indicative for liver processes [15,16]. In this prospective
clinical cohort study we evaluated if the serum levels of miR-122
might be a suitable parameter for disease severity and prognosis in
patients with liver cirrhosis. Our data obtained in two independent
patient cohorts suggest that serum miR-122 is an indicator for
impaired liver function and independent new parameter for
survival of patients with liver cirrhosis. The miR-122 levels were
significantly lower in patients with hepatic decompensation.
Categorization of the patients in groups of low and high miR-
122 serum concentration revealed that patients with low miR-122
serum levels had shorter survival times than patients with higher
serum miR-122 levels. Thus, the serum miR-122 level might be
a useful prognostic parameter in patients with liver cirrhosis,
supplementing the MELD score in assessing the risk of death. In
fact, the multivariate Cox regression analysis revealed that the
MELD score and the serum miR-122 level were independently
associated with the survival time, suggesting that the serum miR-
122 level provides additional prognostic information to the MELD
score. Similarly, in the validation cohort lower miR-122 serum
levels were found in patients with decompensated liver disease
confirming the initial results and suggesting that serum miR-122
levels are indicators of hepatic functional capacity. Combining the
overall survival data of both cohorts lead to a highly significant
difference concerning overall survival between patients with higher
and lower miR-122 serum concentrations. The suggestion that
miR-122 levels are associated with hepatic functional capacity is
supported by our findings that low serum miR-122 levels were
associated with the presence of hepatorenal syndrome, ascites and
spontaneous bacterial peritonitis, all of which are associated with
shorter survival of patients.
Similar to previous studies in patients with chronic or acute liver
damage [22–27], we found a positive correlation between the
serum level of miR-122 and serum aminotransferases, indicating
that miR-122 represents at least in part ongoing liver damage and
cell death. In addition, there was a strong negative correlation
between serum miR-122 levels and INR in our patients with liver
cirrhosis, which was not observed in patients with HCV-induced
chronic hepatitis [22]. It can be anticipated that the release of
miR-122 from necrotic hepatocytes, secretion of miR-122 from
hepatocytes within nanovesicles [28] and reduced degradation are
the major sources of extracellularly circulating miR-122. Further-
more, distribution may also be a relevant factor. If release from
necrotic hepatocytes or reduced degradation were the major
source of serum miR-122, a positive correlation between hepatic
complications and miR-122 should be expected. In the present
study, however, we observed lower levels of miR-122 in patients
with more advanced disease, indicating that reduced serum miR-
122 is most likely the result of reduced release from heptocytes.
Another possibility is that miR-122 serum levels are reduced due
to higher volume distribution in patients with ascites. This
indicates that in patients with liver cirrhosis, the miR-122 serum
level might be a marker for hepatic functional capacity, whereas at
earlier stages of liver disease, the serum miR-122 level is mainly an
indicator of necroinflammatory activity and cell death in the liver.
As release from damaged hepatocytes might be the major source
of hepatocyte-derived miRs [19], it is conceivable that in cirrhotic
patients who lost a big proportion of hepatocytes and thus have
less functional hepatic capacity, the release of miRs upon damage
might be lower than in patients with higher amounts of healthy
liver tissue.
An additional finding of the present study is the inverse
correlation between the serum concentrations of miR-122 and
creatinine. Patients with hepatorenal syndrome had highly
significant lower miR-122 serum levels than patients without this
complication. Different from the present study in a recent
publication no correlation between serum miR-122 and creatinine
levels was found in patients with toxic liver damage [22]. The
differences in these findings are probably due to the different
pathogenesis of liver failure and concomitant kidney failure
between acute-on-chronic decompensation in our patients and
acute drug-induced liver failure in the other cohort [22]. In our
patients low miR-122 serum levels were correlated with de-
terioration of liver capacity which is accompanied by kidney
failure, whereas in acute liver damage, enhanced miR-122 levels
represent hepatocyte damage and death [21,22]. However, we did
not find any correlation between the serum levels of miR-122 and
Table 3. Univariate and multivariate analysis of parameters
associated with overall survival.
Univariate analysis Multivariate analysis
Parameter HR 95% CI P value HR 95% CI P value
low
miR-122
3.259 1.252–
8.484
0.016 3.405 1.295–
8.951
0.013
MELD ,18 0.262 0.126–
0.545
,0.001 0.212 0.098–
0.460
,0.001
Male Sex 0.521 0.257–
1.054
0.070 0.353 0.170–
0.734
0.005
Age ,65
years
0.717 0.356–
1.446
0.353
Abbreviations:
HR, hazard ratio; CI, confidence interval; MELD, model of end stage liver disease.
doi:10.1371/journal.pone.0045652.t003
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PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e45652Figure 4. Serum miR-122 levels in the validation cohort and overall survival in the combined cohort. (A) Serum miR-122 in patients with
and without hepatic decompensation. (B) miR-122 levels in patients with and without ascites. The vertical lines indicate the range, the horizontal
boundaries of the boxes represent the first and third quartile. The analysis was performed with Kruskal-Wallis test and the Bonferroni correction was
used for the sub-analysis. The number of patients in each group is indicated in the figure. (C) Survival curves for patients in the validation cohort with
high or low serum miR-122 levels. The analysis was performed with the Cox regression model. (D) Survival curves for patients in the combined cohort
with high or low serum miR-122 levels. The analysis was performed with the Cox regression model.
doi:10.1371/journal.pone.0045652.g004
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be that patients with heavily impaired liver function often receive
parenteral albumin substitution which adulterates the measured
protein serum levels. Furthermore, bilirubin and albumin levels
may vary depending on nutrition status, drug use or cholestasis
and are biased by different half-life times and thus are not the most
reliable indicators of liver function [29].
In summary, the data of the present study indicate that the
serum level of the hepatocyte specific miR-122 is reduced in
patients with hepatic decompensation, and that lower miR-122
levels are associated with ascites, spontaneous bacterial peritonitis
and hepatorenal syndrome. Lower miR-122 concentrations were
associated with mortality independently from the MELD score.
Therefore, serum miR-122 is a new potential parameter for liver
function and a prognostic parameter in patients with liver
cirrhosis.
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